PAVM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PAVM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PAVmed's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.
The historical data trend for PAVmed's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAVmed Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
ROCE % | Get a 7-Day Free Trial | - | - | -142.19 | -221.17 | - |
PAVmed Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROCE % | Get a 7-Day Free Trial | -640.44 | -801.18 | - | - | - |
PAVmed's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -78.674 | / | ( ( (53.98 - 41.2) | + | (33.119 - 54.177) ) | / 2 ) | |
= | -78.674 | / | ( (12.78 | + | -21.058) | / 2 ) | |
= | -78.674 | / | -4.139 | ||||
= | 1,900.80 % |
PAVmed's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -73.984 | / | ( ( (33.119 - 54.177) | + | (37.254 - 55.015) ) | / 2 ) | |
= | -73.984 | / | ( ( -21.058 | + | -17.761 ) | / 2 ) | |
= | -73.984 | / | -19.4095 | ||||
= | 0 % |
(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAVmed (NAS:PAVM) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of PAVmed's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J Glennon | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
Michael Adam Gordon | officer: General Counsel | ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165 |
Shaun O'neil | officer: Chief Operating Officer | ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165 |
James L Cox | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
Debra White | director | C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165 |
Ronald M Sparks | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
Brian J. Deguzman | officer: Chief Medical Officer | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
Dennis M Mcgrath | officer: President & CFO | C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165 |
Lishan Aklog | director, 10 percent owner, officer: Chairman and CEO | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171 |
Joan B Harvey | director | ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165 |
Timothy E Baxter | director | ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165 |
Matthew Sirovich | 10 percent owner | C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123 |
Ira Scott Greenspan | director | 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106 |
David S. Battleman | director | C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019 |
Joshua R Lamstein | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
From GuruFocus
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire PRNewswire • 06-14-2023
By Business Wire Business Wire • 11-03-2022
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire • 07-31-2023
By Business Wire Business Wire • 01-11-2023
By PRNewswire PRNewswire • 04-19-2023
By Business Wire Business Wire • 08-30-2022
By PRNewswire PRNewswire • 04-25-2023
By PRNewswire PRNewswire • 04-22-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.